Apostolia M. Tsimberidou

Author

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

A M. Tsimberidou, A TSIMBERIDOU, A Tsimberidou, A-M Tsimberidou, A. M. Tsimberidou, A. Tsimberidou, A.-M. Tsimberidou, A.M. Tsimberidou, AM Tsimberidou, Apostalia M. Tsimberidou

998

Publications

22.9K

Citations

H-Index

138

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center University of California San Diego Advanced Cancer Therapeutics Moores Cancer Center Sarah Cannon

About

Apostolia M. Tsimberidou is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	38	103	6K
2	Health Sciences	19	31	1.2K
3	Engineering	9	9	1.5K
4	Nursing	1	1	13
5	Public Health	1	1	29

Apostolia M. Tsimberidou

246

Publications

15.4K

Citations

H-Index

Page 1

	Year	Citations
Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial Jordi Rodón, Jean‐Charles Soria, Raanan Berger, Nature Medicine Radiation OncologyEngineeringTranscriptomic ProfilingTumor HeterogeneityMedicine	2019	570
Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative Apostolia M. Tsimberidou, Nancy G. Iskander, David S. Hong, Clinical Cancer Research	2012	528
PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring <i>PIK3CA</i> Mutations Filip Jankú, Jennifer J. Wheler, Shannon N. Westin, Journal of Clinical Oncology	2012	447
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials Timothy A. Yap, Naval Daver, Mikhila Mahendra, Nature Medicine Hematological MalignancyOncologyBiochemistryMedicineAcute Myeloid Leukemia	2023	335
<i>PIK3CA</i> Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors Filip Jankú, Apostolia M. Tsimberidou, Ignacio Garrido‐Laguna, Molecular Cancer Therapeutics Tumor BiologyAdvanced CancersMedicineCancer Cell BiologyPathology	2011	328
Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells Chad Tang, James W. Welsh, Patricia M. de Groot, Clinical Cancer Research	2016	309
Clinical Outcomes and Prognostic Factors in Patients With Richter's Syndrome Treated With Chemotherapy or Chemoimmunotherapy With or Without Stem-Cell Transplantation Apostolia M. Tsimberidou, Susan O’Brien, Issa F. Khouri, Journal of Clinical Oncology	2006	297
<i>PIK3CA</i> Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials Filip Jankú, Jennifer J. Wheler, Aung Naing, Cancer Research EngineeringGeneticsPathologyTumor BiologySignaling Pathway	2012	295
Other Malignancies in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Apostolia M. Tsimberidou, Sijin Wen, Peter McLaughlin, Journal of Clinical Oncology	2008	238
Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study Jennifer J. Wheler, Filip Jankú, Aung Naing, Cancer Research EngineeringPathologyCancer RegistrationTumor BiologyTumor Heterogeneity	2016	232

Page 1